Anne Iacobucci

Learn More
PURPOSE Mapatumumab (TRM-1, HGS-ETR1) is a fully human agonistic monoclonal antibody that targets and activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 1 (death receptor 4). Mapatumumab functions like the natural receptor ligand, TRAIL, a tumor necrosis factor superfamily member that is an important mediator of apoptosis in(More)
2533 Background: TRAIL is a member of the TNF ligand superfamily. There is strong evidence for its ability to induce apoptosis in cancer cell lines. TRAIL causes apoptosis via 2 death receptors [DR4 (TRAIL-R1) & DR5 (TRAIL-R2)] which are upregulated in different cancer cell types. TRM-1 (HGS-ETR1) is a fully human monoclonal antibody agonistic to TRAIL-R1(More)
3528 Background: Decitabine (D), a hypomethylating agent, and vorinostat (V), a histone deacetylase inhibitor, belong to two different classes of drugs with an epigenetic effect. The ideal dose scheduling of these drugs remains controversial. This phase I study aims to determine the recommended phase II dose (RPTD) of the combination, their toxicity(More)
  • 1